Silver Book Fact

Economic value from flu vaccine in elderly

As over 60% of the economic burden of influenza falls on those ages 65 and older, programs to reduce the impact of influenza on older Americans would have the greatest economic benefit.

Molinari, Noelle-Angelique M., Ismael R. Ortega-Sanchez, Mark L. Messonnier, William W. Thompson, Pascale M. Wortley, et al. The Annual Impact of Seasonal Influenza in the U.S.: Measuring disease burden and costs. Vaccine. 2007; 25: 5086-96. http://download.thelancet.com/flatcontentassets/H1N1-flu/epidemiology/epidemiology-14.pdf

Reference

Title
The Annual Impact of Seasonal Influenza in the U.S.: Measuring disease burden and costs
Publication
Vaccine
Publication Date
2007
Authors
Molinari, Noelle-Angelique M., Ismael R. Ortega-Sanchez, Mark L. Messonnier, William W. Thompson, Pascale M. Wortley, et al.
Pages
5086-96
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Cost effectiveness of MMR vaccine
    For every dollar spent on the MMR (measles, mumps, and rubella) vaccine, $21 is saved.  
  • Significant savings from zoster vaccine
    In a cost-effectiveness analysis, investigators estimated the zoster vaccine cost $44,000 per quality-adjusted life year saved for a 70-year-old woman.  
  • Influenza vaccine use reduces antibiotic use
    Use of LAIV (live attenuated influenza virus) in healthy adults ages 18 to 65 reduced antibiotic use by 43% to 47%.  
  • Use of shingles vaccine could save $82 to $103 million
    Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles,…  
  • New antibacterial agents between 1983 and 2012
    Total number of new antibacterial agents is in decline